Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NMT1 | P30419 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22674771 | 0.81 | SMN1; SMN2 (0.67) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL1275920 | 0.80 | ALDH1A1 (0.70) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL6850999 | 0.80 | KDM4E (0.79) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL455439 | 0.80 | TDP1 (0.70) | TDP1POLBNPC1RAB9AMAPT | |
| Fluoride SCHEMBL11790965 | 0.78 | TDP1 (0.67) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL2093333 | 0.78 | TDP1 (0.67) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL61417 | 0.78 | TDP1 (1.00) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL19965684 | 0.77 | TDP1 (0.59) | TDP1POLBNPC1RAB9AMAPT | |
| SCHEMBL23752424 | 0.76 | MEN1 (0.61) | TDP1NPC1RAB9AMAPTTGM2 | |
| SCHEMBL19987511 | 0.76 | ALDH1A1 (0.61) | POLBNPC1RAB9AMAPTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2025-04-22 | — | — | US | disclosed |
| CN-111099941-B | Preparation method of alkyl nitrile compound | 中国科学院上海有机化学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-115103670-A | Transcription Enhancement Associated Domain (TEAD) transcription factor inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115066263-A | Directed conjugation techniques | 克莱奥药品有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114751903-A | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | 上海凌达生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-108588151-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-05-13 | — | — | CN | disclosed |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) | 2022-04-28 | — | — | US | disclosed |
| CN-114206389-A | Multivalent ligand clusters for targeted delivery of therapeutic agents | 有丝分裂疗法有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114146056-A | Modular compositions for scavenging soluble biomolecules and methods related thereto | 纳米提克斯有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-108546643-B | Process for large scale enzymatic synthesis of oligosaccharides | 台湾地区“中央研究院” | 2022-02-25 | — | — | CN | disclosed |
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| CN-105849099-B | Polycyclic inhibitors of cyclin dependent kinase 7(CDK7) | 达纳-法伯癌症研究所股份有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-110698460-A | Heteroaryl compound, preparation method, pharmaceutical composition and application thereof | 隆泰申医药科技(南京) 有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-106074591-B | RNA interference in ocular symptoms | 菲奥医药公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-109136974-B | C (sp) -containing2) Process for producing (E) -N bond compound | 中国科学院上海有机化学研究所 | 2019-12-31 | — | — | CN | disclosed |
| CN-105792852-B | Glucose-responsive insulin conjugates | 默沙东公司 | 2019-12-10 | — | — | CN | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190125750-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2019-05-02 | — | — | US | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639310-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | TDP1 1172/4885POLB 430/4885NPC1 4797/4885 |
| US-20190125750-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | TDP1 1172/4885POLB 430/4885NPC1 4797/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | TDP1 316/4885POLB 1763/4885NPC1 4636/4885 |
| US-12281118-B2 | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | PTPN1, PTPN7, PTPN9 | TDP1 3328/4885POLB 4105/4885NPC1 3718/4885 |
| US-20220127271-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE | PTPN1, PTPN7, PTPN9 | TDP1 3328/4885POLB 4105/4885NPC1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.